These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 4724190)

  • 1. Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Agid Y; Javoy F; Youdim MB
    Br J Pharmacol; 1973 May; 48(1):175-8. PubMed ID: 4724190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldehyde dehydrogenase and monoamine oxidase in the striatum of cats with nigrostriatal lesions.
    Duncan RJ; Sourkes TL; Boucher R; Poirier LJ; Roberge A
    J Neurochem; 1972 Aug; 19(8):2007-10. PubMed ID: 5047860
    [No Abstract]   [Full Text] [Related]  

  • 3. In vivo labelling and axonal transport of monoamine oxidase in the rat basal ganglia using radioactive pargyline.
    Gramsbergen JB; Sebens JB; Korf J
    J Neural Transm; 1986; 66(1):21-36. PubMed ID: 2426396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system.
    Javoy F; Sotelo C; Herbet A; Agid Y
    Brain Res; 1976 Feb; 102(2):201-15. PubMed ID: 1247882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
    Demarest KT; Smith DJ; Azzaro AJ
    J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome.
    Ungerstedt U
    Pharmacol Ther B; 1976; 2(1):37-40. PubMed ID: 772721
    [No Abstract]   [Full Text] [Related]  

  • 7. Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system: lesion studies.
    Pollard H; Llorens C; Schwartz JC; Gros C; Dray F
    Brain Res; 1978 Aug; 151(2):392-8. PubMed ID: 209865
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term increase and long-term reversion of striatal cell activity after degeneration of the nigrostriatal dopamine system.
    Schultz W; Ungerstedt U
    Exp Brain Res; 1978 Oct; 33(2):159-71. PubMed ID: 700003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catecholamine-metabolizing enzyme activity in the nigrostriatal system.
    Francis A; Whittemore R; Jeffery DR; Pearce LB; Roth JA
    Biochem Pharmacol; 1987 Jul; 36(13):2229-31. PubMed ID: 3111478
    [No Abstract]   [Full Text] [Related]  

  • 11. Demonstration of the nigrostriatal projection by silver staining after nigral injections of 6-hydroxydopamine.
    Maler L; Fibiger HC; McGeer PL
    Exp Neurol; 1973 Aug; 40(2):505-15. PubMed ID: 4125858
    [No Abstract]   [Full Text] [Related]  

  • 12. Temporal changes in amine synthesizing enzymes of rat extrapyramidal structures after hemitransections or 6-hydroxydopamine administration.
    McGeer EG; Fibiger HC; McGeer PL; Brooke S
    Brain Res; 1973 Mar; 52():289-300. PubMed ID: 4144770
    [No Abstract]   [Full Text] [Related]  

  • 13. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
    Ungerstedt U; Ljungberg T; Steg G
    Adv Neurol; 1974; 5():421-6. PubMed ID: 4531217
    [No Abstract]   [Full Text] [Related]  

  • 14. Basal ganglia dopamine depletion does not alter D1 dopamine receptor binding properties.
    Trugman JM; Pronsky CJ; Wooten GF
    Adv Neurol; 1990; 53():107-10. PubMed ID: 2146858
    [No Abstract]   [Full Text] [Related]  

  • 15. Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid.
    Buisson A; Pateau V; Plotkine M; Boulu RG
    Neurosci Lett; 1991 Oct; 131(2):257-9. PubMed ID: 1837072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of aldehyde dehydrogenase, aldehyde reductase, and acetylcholine esterase in striatum of rats bearing electrolytic lesions of the medial forebrain bundle.
    Duncan RJ; Sourkes TL; Dubrovsky BO; Quik M
    J Neurochem; 1975 Jan; 24(1):143-7. PubMed ID: 234146
    [No Abstract]   [Full Text] [Related]  

  • 17. The in vivo effect of tropolone on dopamine metabolism and the catechol-O-methyl transferase activity in the striatum of the rat.
    Broch OJ
    Acta Pharmacol Toxicol (Copenh); 1972; 31(3):217-25. PubMed ID: 5068602
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway.
    Vrana SL; Azzaro AJ; Vrana KE
    Mol Pharmacol; 1992 May; 41(5):839-44. PubMed ID: 1350320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective degeneration of central dopaminergic systems after injection of 6-hydroxydopamine in the ventral mesencephalic tegmentum of the rat. Demonstration by the Fink-Heimer strain.
    Simon H; LeMoal M; Galey D; Cardo B
    Exp Brain Res; 1974; 20(4):375-84. PubMed ID: 4139037
    [No Abstract]   [Full Text] [Related]  

  • 20. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants.
    Björklund A; Stenevi U
    Brain Res; 1979 Nov; 177(3):555-60. PubMed ID: 574053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.